Strategic Initiative

Slingshot members are tracking this corporate initiative:

ImmunoGen (IMGN) and Merck (MRK) Announce Research Collaboration to Evaluate IMGN's Mirvetuximab Soravtansine with Keytruda in Folate Receptor Alpha-Positive Ovarian Cancer

Source Link:: http://seekingalpha.com/news/3082516-immunogen-evaluate-combo-lead-product-candidate-mercks-keytruda-ovarian-cancer

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies

Importance

High

Medium

Low

Impact on Stocks

MRK

100%

IMGN

100%

SIGN ME UP
I want to vote! LOG ME IN
Now!

Slingshot Insights Explained

JOIN FOR FREE TODAY

Strategic Initiative Date

Announcement Date:

Feb 04, 2016

Relevance Tracked Until:

Q1, 2017

Related Projects

Don’t see a project related to the strategic initiative you care about?

Related Keywords Research Collaboartion, Mirvetuximab Soratansine, Keytruda, Folate Receptor, Alpha-positive, Ovarian Cancer, Phase 1b/2 Forward Ii Trial